BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Monitra Health gets US patent for advanced wireless cardiac monitoring technology

24 November 2024 | News

Plans to commercialise this breakthrough technology, expanding its presence in key markets



Hyderabad-based startup Monitra Healthcare, a pioneer in health monitoring technologies, has announced the grant of its US Patent No. 12,109,029 B2, titled Wireless Cardiac Monitoring Device and Method to Measure and Transmit Cardiac Physiological Signals. This patent, issued by the United States Patent and Trademark Office, marks a significant milestone in Monitra Health’s mission to revolutionise cardiac care through innovation.

The patented technology introduces a wireless patch-based cardiac monitoring device designed to enhance patient compliance and diagnostic accuracy. Unlike current products, the patch automatically detects its orientation on the patient and optimally selects electrode pairs to ensure the highest quality signal transmission, eliminating errors from improper placement. The device processes bio-potential signals in real-time and wirelessly transmits physiological data to external systems for further analysis.

The innovation features advanced orientation detection to reliably identify and adapt to the patch’s placement on the patient. Its dynamic electrode pairing optimizes performance by automatically selecting the most effective electrode pairs based on real-time orientation and signal quality. Seamless wireless connectivity enables efficient transmission of ECG and other physiological data to external devices for immediate processing and analysis. Additionally, the device's lightweight, wire-free design ensures superior patient comfort, making it ideal for prolonged use.

Monitra Health's patented technology promises to redefine ambulatory ECG monitoring, particularly for conditions like atrial fibrillation and other cardiac arrhythmias and QT prolongation monitoring in cardiac safety studies in clinical trials.The company plans to commercialise this breakthrough technology, expanding its presence in key markets, including the U.S., U.K., and Australia, to further strengthen its leadership in the healthcare technology sector.